BTLA and neoplasm: B and T lymphocyte attenuators (BTLAs) were reported to be identified mostly on B lymphocytes rather than on T lymphocytes and natural killer cells, and the combination of chemotherapy and the anti-BTLA antibody reduced the peritoneal tumor volume and extended survival in tumor-bearing mice [31].